» Articles » PMID: 26307636

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2015 Aug 27
PMID 26307636
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.

Citing Articles

Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment.

Martinez-Sobrido L, Nogales A Int J Mol Sci. 2024; 25(19).

PMID: 39408912 PMC: 11476892. DOI: 10.3390/ijms251910584.


4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.

Lieber C, Aggarwal M, Yoon J, Cox R, Kang H, Sourimant J PLoS Pathog. 2023; 19(4):e1011342.

PMID: 37068076 PMC: 10138230. DOI: 10.1371/journal.ppat.1011342.


Treatment of Respiratory Viral Coinfections.

Alexander P, Dobrovolny H Epidemiologia (Basel). 2022; 3(1):81-96.

PMID: 36417269 PMC: 9620919. DOI: 10.3390/epidemiologia3010008.


Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase.

Sourimant J, Lieber C, Yoon J, Toots M, Govindarajan M, Udumula V Sci Adv. 2022; 8(25):eabo2236.

PMID: 35749502 PMC: 9232112. DOI: 10.1126/sciadv.abo2236.


Generation of a pdmH1N1 2018 Influenza A Reporter Virus Carrying a mCherry Fluorescent Protein in the PA Segment.

Bu L, Chen B, Xing L, Cai X, Liang S, Zhang L Front Cell Infect Microbiol. 2022; 11:827790.

PMID: 35127568 PMC: 8811159. DOI: 10.3389/fcimb.2021.827790.


References
1.
Stiver G . The treatment of influenza with antiviral drugs. CMAJ. 2003; 168(1):49-56. PMC: 139319. View

2.
Hallak L, Spillmann D, Collins P, Peeples M . Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol. 2000; 74(22):10508-13. PMC: 110925. DOI: 10.1128/jvi.74.22.10508-10513.2000. View

3.
Guerrero C, Guererero C, Murillo A, Acosta O . Inhibition of rotavirus infection in cultured cells by N-acetyl-cysteine, PPARγ agonists and NSAIDs. Antiviral Res. 2012; 96(1):1-12. DOI: 10.1016/j.antiviral.2012.06.011. View

4.
Boutros M, Bras L, Huber W . Analysis of cell-based RNAi screens. Genome Biol. 2006; 7(7):R66. PMC: 1779553. DOI: 10.1186/gb-2006-7-7-R66. View

5.
Patel D, Patel A, Nolan W, Zhang Y, Holtzman M . High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One. 2012; 7(5):e36594. PMC: 3344904. DOI: 10.1371/journal.pone.0036594. View